According to the latest market research study published by P&S Intelligence, the global pharmacovigilance market is poised for significant growth, with projections indicating a rise from USD 8,340.1 million in 2024 to USD 18,026.7 million by 2030, reflecting a CAGR of 13.9%. This expansion is primarily driven by the increasing incidence of adverse drug reactions (ADRs) and a heightened focus on drug safety and efficacy. Additionally, the integration of artificial intelligence (AI) and machine le
pharmacovigilance (2)
For more information, contact: ExL Events FOR IMMEDIATE RELEASE
Phone: 866-207-6528
Email: registration@exlevents.com
“Ply Emerging Technologies and Effective SOPs to Enhance Regulatory Compliance and the Quality of Your Safety System”
ExL Events is hosting the 4th Adverse Events Reporting and Safety Strategies Summit on December 4–5, 2017 at the Sonesta Philadelphia Rittenhouse Square in Philadelphia, PA.
This summit will offer an in-depth analysis of real-world dat